MACOP-B Chemotherapy for the treatment of high grade and intermediate grade Non Hodgkin's lymphoma
暂无分享,去创建一个
F. Herrmann | R. Mertelsmann | W. Oster | A. Lindemann | W. Thoenes | H. Kreiter | T. Forsthuber | H. Gamm | R. Hinterberger | G. Schmitz | H. Fuhr | H. H. Hennekeuser
[1] R A Olshen,et al. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] R. Larson,et al. Long-term survival of patients with intermediate and high grade lymphoma treated with COMLA/ABP. , 1990, Leukemia.
[3] M. Engelhard,et al. German-austrian multicenter trial for aggressive non-Hodgkin lymphomas: COP-BLAM/IMVP-16 chemotherapy with randomized adjuvant radiotherapy , 1988, Blut.
[4] Goldie Jh,et al. Impact of dose-intense chemotherapy on the development of permanent drug resistance. , 1987 .
[5] E J Freireich,et al. Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. , 1987, Science.
[6] W. Velasquez,et al. Results of MIME salvage regimen for recurrent or refractory lymphoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Jaffe Es. Relationship of classification to biologic behavior of non-Hodgkin's lymphomas. , 1986 .
[8] D. Weisenburger,et al. Chemotherapy for diffuse large-cell lymphoma--rapidly responding patients have more durable remissions. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] J. Connors,et al. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. , 1985, Annals of internal medicine.
[10] R. Fisher,et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. , 1983, Annals of internal medicine.
[11] G. Pinkus,et al. Improved prognosis of diffuse histiocytic and undifferentiated lymphoma by use of high dose methotrexate alternating with standard agents (M-BACOD). , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] J. Armitage,et al. Predicting therapeutic outcome in patients with diffuse histiocytic lymphoma treated with cyclophosphamide, adriamycin, vincristine and prednisone (CHOP) , 1982, Cancer.
[13] F. Cabanillas,et al. IMVP-16: an effective regimen for patients with lymphoma who have relapsed after initial combination chemotherapy. , 1982, Blood.
[14] M. Pasmantier,et al. Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen. , 1982, Annals of internal medicine.
[15] R. Fisher,et al. Factors predicting long-term survival in diffuse mixed, histiocytic, or undifferentiated lymphoma. , 1981, Blood.
[16] L. Norton,et al. Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival. , 1980, Blood.
[17] V. Devita,et al. Bleomycin, adriamycin, cyclophosphamide, vincristine, and prednisone (BACOP) combination chemotherapy in the treatment of advanced diffuse histiocytic lymphoma. , 1976, Annals of internal medicine.
[18] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[19] C. Spurr,et al. Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids. , 1968, Cancer research.
[20] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[21] Robert N. Hughes,et al. Cancer: Principles and Practice of Oncology , 2005 .
[22] F. Herrmann,et al. Minimal peripheral blood cells carrying clonal markers of B cell disorders: evidence for monoclonality of circulating lymphocytes in patients with multiple myeloma. , 1989, International journal of cell cloning.
[23] J. Goldie,et al. Impact of dose-intense chemotherapy on the development of permanent drug resistance. , 1987, Seminars in oncology.
[24] E. Jaffe. Relationship of classification to biologic behavior of non-Hodgkin's lymphomas. , 1986, Seminars in oncology.
[25] D. Rosenthal,et al. Methotrexate as a single agent and in combination chemotherapy for the treatment of non-Hodgkin's lymphoma of unfavorable histology. , 1981, Cancer treatment reports.